Larimar Therapeutics Inc (LRMR)
6.33
-0.13
(-2.01%)
USD |
NASDAQ |
Apr 25, 16:00
6.30
-0.03
(-0.47%)
After-Hours: 20:00
Larimar Therapeutics Total Liabilities (Quarterly): 14.22M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.22M |
| September 30, 2023 | 11.24M |
| June 30, 2023 | 11.79M |
| March 31, 2023 | 12.67M |
| December 31, 2022 | 15.50M |
| September 30, 2022 | 14.35M |
| June 30, 2022 | 12.80M |
| March 31, 2022 | 14.12M |
| Date | Value |
|---|---|
| December 31, 2021 | 14.25M |
| September 30, 2021 | 15.87M |
| June 30, 2021 | 13.41M |
| March 31, 2021 | 14.24M |
| December 31, 2020 | 14.99M |
| September 30, 2020 | 11.32M |
| June 30, 2020 | 12.91M |
| December 31, 2019 | 5.895M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
5.895M
Minimum
Dec 2019
15.87M
Maximum
Sep 2021
13.10M
Average
13.76M
Median
Total Liabilities (Quarterly) Benchmarks
| Cogent Biosciences Inc | 55.64M |
| ACADIA Pharmaceuticals Inc | 317.20M |
| PTC Therapeutics Inc | 2.714B |
| Renovaro Inc | 14.42M |
| G1 Therapeutics Inc | 86.15M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 95.94M |
| Shareholders Equity (Quarterly) | 81.72M |